Zinapar darinaparsin: Phase I started

Solasia began an open-label, Japanese Phase I trial to evaluate 200 and 300 mg/m 2 IV darinaparsin for 5 consecutive days in a 28-day cycle for up to 4 cycles in about 9 patients with relapsed or refr...